Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment. (Q38221095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Thorsten Hornung

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

981-998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

Polymyositis and dermatomyositis (first of two parts)

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Evidence for a role of type I interferons in the pathogenesis of dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Pathogenic mechanisms of disease in myositis: autoantigens as clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

21 January 2018

Myositis autoantibodies

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Type 1 interferons and myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Type I interferon pathway in adult and juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Role of cytokines and chemokines in idiopathic inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Immunopathogenesis of juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Uncertainties in the pathogenesis of adult dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Dermatomyositis after interferon alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

An update on pathogenic mechanisms of inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Pathogenesis, classification and treatment of inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Whole microvascular unit deletions in dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Positive association between STAT4 polymorphisms and polymyositis/dermatomyositis in a Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Skin disease in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

New approaches to the assessment and treatment of the idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Cutaneous dermatomyositis: an updated review of treatment options and internal associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Treatment of dermatomyositis with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Mycophenolate mofetil for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

The management of dermatomyositis: current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Not all intravenous immunoglobulin preparations are equally well tolerated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Inflammatory myopathies: management of steroid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Azathioprine with prednisone for polymyositis. A controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Abatacept as a successful therapy for myositis—a case-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Taming lupus-a new understanding of pathogenesis is leading to clinical advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Methotrexate for the treatment of cutaneous dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Prednisone and azathioprine for polymyositis: long-term followup.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Abatacept for treatment of refractory polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0240-6

Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis

21 January 2018

1 reference

12 December 2020

Guidelines of care for dermatomyositis. American Academy of Dermatology

1 reference

12 December 2020

Hydroxychloroquine neuromyotoxicity

1 reference

12 December 2020

The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'

1 reference

12 December 2020

Treatment of dermatomyositis with methotrexate and prednisone

1 reference

12 December 2020

1 reference

12 December 2020

Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies.

1 reference

12 December 2020

Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases

1 reference

12 December 2020

Long-term follow-up of 62 patients with myositis

1 reference

12 December 2020

The Yin and Yang of TNF-{alpha} inhibition

1 reference

12 December 2020

Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis

1 reference

12 December 2020

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

12 December 2020

1 reference

12 December 2020

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

12 December 2020

The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis

1 reference

12 December 2020

Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center

1 reference

12 December 2020

High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels

1 reference

12 December 2020

Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis

1 reference

12 December 2020

Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis

1 reference

12 December 2020

Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis

1 reference

12 December 2020

Use of antimalarials in dermatology

1 reference

12 December 2020

Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases

1 reference

12 December 2020

Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis

1 reference

12 December 2020

Adjunctive use of hydroxychloroquine in childhood dermatomyositis

1 reference

12 December 2020

Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature

1 reference

12 December 2020

Survival in polymyositis: corticosteroids and risk factors

1 reference

12 December 2020

Dermatomyositis: immunopathologic study of skin lesions.

1 reference

12 December 2020

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases

1 reference

12 December 2020

Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study

1 reference

12 December 2020

Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.

1 reference

12 December 2020

Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions

1 reference

12 December 2020

DERMATOMYOSITIS. REPORT OF A PATIENT TREATED WITH HYDROXYCHLOROQUINE SULFATE (PLAQUENIL)

1 reference

12 December 2020

Efficacy of intravenous Ig therapy in juvenile dermatomyositis

1 reference

12 December 2020

Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis

1 reference

12 December 2020

Update: biomarkers for idiopathic inflammatory myopathies

1 reference

12 December 2020

Treatment of recalcitrant dermatomyositis with efalizumab

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies

1 reference

12 December 2020

Cyclosporine A as treatment of esophageal involvement in dermatomyositis

1 reference

12 December 2020

Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis

1 reference

12 December 2020

Anti-PL7 antisynthetase syndrome under interferon therapy

1 reference

12 December 2020

10.1007/S40265-014-0240-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 March 2020

1006170151

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939511%20AND%20SRC:MED&resulttype=core&format=json